Evidence map›Paper›PMID 35603297›Full record

ArticleCommunications medicine2022

Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients.

Ngai Sze Wong, Shui Shan Lee, Denise P C Chan, Timothy C M Li, Tracy H Y Ho, Fion W L Luk, Kai Ming Chow, Eugene Y K Tso, Eng-Kiong Yeoh, Samuel Y S Wong and 2 more

Open access · goldAbstract read
In one paragraph

Article in Communications medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Ngai Sze Wong *Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, Shatin China.ORCID 0000-0003-3788-8114
Shui Shan Lee *Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, Shatin China.ORCID 0000-0003-1448-765X
Denise P C ChanStanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, Shatin China.
Timothy C M LiDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Shatin China.
Tracy H Y HoDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Shatin China.
Fion W L LukDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Shatin China.
Kai Ming ChowDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Shatin China.ORCID 0000-0001-5310-5197
Eugene Y K TsoDepartment of Medicine & Geriatrics, United Christian Hospital, Hong Kong, China.
Eng-Kiong YeohJC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Shatin China.
Samuel Y S WongJC School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Shatin China.
David S C HuiDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Shatin China.ORCID 0000-0003-4382-2445
Grace C Y LuiDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Shatin China.ORCID 0000-0001-5242-2967
Chinese University of Hong Kong · HKUnited Christian Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The adaptive immune responses of COVID-19 patients contributes to virus clearance, restoration of health and protection from re-infection. The patterns of and the associated characteristics with longitudinal neutralising antibody (NAb) response following SARS-CoV-2 infection are important in their potential association with the population risks of re-infection. Methods: This is a longitudinal study with blood samples and clinical data collected in adults aged 18 or above following diagnosis of SARS-CoV-2 infection. NAb levels were measured by the SARS-CoV-2 surrogate virus neutralisation test (sVNT). Anonymous clinical and laboratory data were matched with surveillance data for each subject for enabling analyses and applying latent class mixed models for trajectory delineation. Logistic regression models were performed to compare the characteristics between the identified classes. Results: In 2020-2021, 368 convalescent patients in Hong Kong are tested for NAb. Their seroconversion occur within 3 months in 97% symptomatic patients, the level of which are maintained at 97% after 9 months. The NAb trajectories of 200 symptomatic patients are classified by the initial response and subsequent trend into high-persistent and waning classes in latent class mixed models. High-persistent (15.5%) class patients are older and most have chronic illnesses. Waning class patients (84.5%) are largely young adults who are mildly symptomatic including 2 who serorevert after 10 months. Conclusions: Characteristic sub-class variabilities in clinical pattern are noted especially among patients with waning NAb. The heterogeneity of the NAb trajectory patterns and their clinical association can be important for informing vaccination strategy to prevent re-infection.

Indexed as

AntibodiesViral infection

Identifiers

PMID35603297
PMCPMC9120513
OpenAlexW4280574507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.